Posts

The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex

/by

This review provides a comprehensive overview of the current state of knowledge regarding the pathogenesis, clinical manifestations, and treatment approaches for epilepsy and other neurological features of TSC. While narrative reviews on TSC exist, this review uniquely synthesizes key advancements across the areas of TSC neuropathology, conventional and emerging pharmacological therapies, and targeted treatments. The review is narrative in nature, without any date restrictions, and summarizes the most relevant literature on the neurological aspects and management of TSC. By consolidating the current understanding of TSC neurobiology and evidence-based treatment strategies, this review provides an invaluable reference that highlights progress made while also emphasizing areas requiring further research to optimize care and outcomes for TSC patients.

Read more

Real-World evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex

/by

Highly purified cannabidiol (CBD) has a broad spectrum of action and could be useful for the treatment of drug resistant epilepsy regardless of etiology or syndrome. Multicenter retrospective study that evaluated the efficacy and safety of CBD for the treatment of drug resistant epilepsy of different etiologies in patients >2 years of age.

Read more

Use of cannabinol in the treatment of epilepsy: Lennox-Gastaut Syndrome , Dravet, and Tuberous Sclerosis Complex

/by

Purpose: The objective of this systematic review with meta-analysis was to evaluate the efficiency, safety and short and long term tolerability of Cannabidiol CBD, as an adjunct treatment , in children and adults with Dravet Syndrome (SD) and Lennox Gastaut Syndrome(LGS) or Tuberous Sclerosis Complex with inadequate control of seizures.

Read more